Answer
Yes. Arterial and venous thromboembolic events occurred more often with angiotensin II in its pivotal trial, so preventative measures are normally considered unless contraindicated.
Sources for this answer
- GIAPREZA 2.5 mg/ml concentrate for solution for infusionemc · SmPC Current selected SmPC · Version 3